Actin-related Protein ACTRT3: Potential Drug Target (G84517)

Target Name: ACTRT3

NCBI ID: G84517

ACTRT3

Actin-related Protein ACTRT3: Potential Drug Target

Actin-related protein T3 (ACTRT3) is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of actin dynamics and has been implicated in a number of cellular processes, including cell signaling, cytoskeletal organization, and intracellular transport. Despite its importance, much is still not known about ACTRT3 and its role in the cell.

One of the main challenges in studying ACTRT3 is its complex structure and the difficulty of purifying it from cells. Despite these challenges, researchers have made significant progress in understanding its biology and its potential as a drug target.

Purification and Characterization

ACTRT3 is a protein that is expressed in a wide range of tissues, including muscle, heart, brain, and plasma. It is primarily localized to the endoplasmic reticulum (ER) and is also found in the cytoplasm.

The full-length gene for ACTRT3 has not been fully characterized, but it is believed to contain a unique open reading frame that includes a catalytic domain, a transmembrane segment, and a cytoplasmic tail. The protein is expressed in a variety of cell types and has been shown to be involved in a number of cellular processes.

ACTRT3 has been shown to play a role in regulating actin dynamics and in the regulation of cell signaling. It is a positive regulator of the myosin ATPase, which is responsible for the production of force during muscle contraction. It is also a negative regulator of the protein kinase CK2, which is involved in cell signaling.

In addition to its role in regulating actin dynamics, ACTRT3 has also been shown to play a role in the regulation of cytoskeletal organization. It is a subunit of the microtubule and is involved in the organization of the cytoskeleton.

ACTRT3 has also been shown to play a role in intracellular transport. It is a component of the transport system for the protein involved in the transport of the nucleotide GDP to the cytoskeleton.

Drug Target Potential

ACTRT3 is a protein that has potential as a drug target due to its involvement in a number of cellular processes. Its ability to regulate actin dynamics, cell signaling, cytoskeletal organization, and intracellular transport make it an attractive target for small molecule inhibitors.

One potential approach to targeting ACTRT3 is to use inhibitors of the myosin ATPase, which is a key regulator of actin dynamics. Activating myosin ATPase would cause actin to become more flexible and could potentially lead to muscle relaxation or breakdown.

Another potential approach to targeting ACTRT3 is to use inhibitors of the protein kinase CK2, which is involved in cell signaling. Activating CK2 would cause cells to enter a state of active signaling, which could potentially lead to increased muscle contractions or other cellular processes.

In addition to inhibitors of myosin ATPase and CK2, another potential approach to targeting ACTRT3 is to use inhibitors of the transport system for the protein involved in the transport of the nucleotide GDP to the cytoskeleton. This protein, known as p16, is involved in regulating the movement of nucleotides into the cytoskeleton and is a potential target for small molecule inhibitors.

Conclusion

ACTRT3 is a protein that is involved in a number of cellular processes and has the potential as a drug target. Its ability to regulate actin dynamics, cell signaling, cytoskeletal organization, and intracellular transport make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the biology of ACTRT3 and its potential as a drug target.

Protein Name: Actin Related Protein T3

The "ACTRT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTRT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets